Convergent Therapeutics
Convergent Therapeutics attaches an alpha-emitting isotope to an antibody that homes in on prostate cancer cells, for men whose disease has progressed after standard radioligand treatment. Its lead medicine has reported mid-stage trial results.
Overview
Convergent Therapeutics develops alpha radioantibodies: antibodies that deliver alpha-emitting payloads directly into cancer cells while limiting exposure of healthy tissue. The lead candidate CONV01-α is a PSMA-directed actinium-225 radioantibody for metastatic castration-resistant prostate cancer in patients previously treated with 177Lu-PSMA. In June 2026 the company presented what it described as the largest prospective phase 2 dataset for an alpha radiopharmaceutical at ASCO 2026, reporting anti-tumour activity, durability and favourable tolerability in Lu-PSMA-exposed mCRPC.
Notes
top- The Business Wire releases (ASCO 2026 data, Series A) returned HTTP 403, so funding is omitted; trade press headlines report a USD 90 million Series A (2023) and a USD 40 million extension, unverified here. The domains convergenttx.com and convergenttherapeutics.com are parked; convergentrx.com blocks scripted requests but was fetched via WebFetch.
Similar pages
not linked directly; found by shared links- CompanyFull-Life Technologies
Shares PSMA, Targeted alpha therapy, Actinium-225, Lutetium-177.
- CompanyARTBIO
Shares PSMA, Targeted alpha therapy, Prostate cancer, Lutetium-177.
- TrialA Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC
Shares PSMA, Prostate cancer, Lutetium-177.
- Key paperPhase I dose-escalation study of 225Ac-J591, a PSMA-targeting alpha-emitting antibody, in mCRPC
Shares PSMA, Targeted alpha therapy, Actinium-225, Lutetium-177.
- CompanyActinium Pharmaceuticals
Shares Radio-antibody & radio-ADC, Targeted alpha therapy, Actinium-225, Prostate cancer.
- AgentAAA817
Shares PSMA, Actinium-225, Prostate cancer, Lutetium-177.
- Pairing177Lu-PSMA-617 then 225Ac-PSMA rescue therapy
Shares PSMA, Targeted alpha therapy, Actinium-225, Lutetium-177.
- CompanyAlpha-9 Oncology
Shares Targeted alpha therapy, Actinium-225, Lutetium-177.